SEEG-Guided DBS for Schizophrenia
NCT: NCT07671261 · RECRUITING
Brief Summary
This is a prospective, randomized, interventional study designed to evaluate the efficacy and safety of SEEG-guided deep brain stimulation (DBS) for symptom improvement in patients with treatment-resistant schizophrenia. Using stereo-electroencephalography (SEEG) to record brain activity, we will identify specific abnormal electrophysiological targets and signal features associated with clinical symptoms, followed by a 12-month open-label stimulation period. The study is conducted in three stages: Stage 1 consists of SEEG brain mapping, screening of intervention targets, and optimization of stimulation parameters; Stage 2 consists of DBS implantation surgery and further optimization of stimulation parameters; Stage 3 is a randomized crossover treatment phase, followed by an open-label treatment period.
Frequently Asked Questions
What is SEEG-Guided DBS for Schizophrenia?
SEEG-Guided DBS for Schizophrenia is a clinical trial registered under NCT07671261. Current status: RECRUITING.
What is the status of NCT07671261?
The current status of NCT07671261 (SEEG-Guided DBS for Schizophrenia) is: RECRUITING.
When did SEEG-Guided DBS for Schizophrenia start?
SEEG-Guided DBS for Schizophrenia started on 2025-08-17.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.